SCHEMBL201206

SCHEMBL201206

NC(=O)c1cccc(O)c1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.61
ALDH1A1 P00352 3/20 0.61
HPGD P15428 2/20 0.61
MAPT P10636 1/20 0.61
TSHR P16473 1/20 0.61
HSD17B10 Q99714 1/20 0.61
LCK P06239 1/20 0.46
G6PD P11413 1/20 0.45
CASP7 P55210 1/20 0.45
CASP6 P55212 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
CES2 O00748 1/20 0.43
BCHE P06276 1/20 0.43
CES1 P23141 1/20 0.43
AKR1C3 P42330 1/20 0.42
AKR1C2 P52895 1/20 0.42
AKR1C1 Q04828 1/20 0.42
METAP2 P50579 1/20 0.42
HSD17B14 Q9BPX1 3/20 0.41
CA1 P00915 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27214503 0.86 ALDH1A1 (0.52) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL27730957 0.83 KDM4E (0.52) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL10956901 0.82 HSD17B1 (0.50) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL29528396 0.80 CES2 (0.68) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL10457470 0.80 KDM4E (0.46) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL203112 0.80 CES2 (0.68) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL5231025 0.80 ALDH1A1 (0.60) KDM4EALDH1A1HPGDTSHRHSD17B10
SCHEMBL1067211 0.78 THRB (0.52) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL30623038 0.78 MMP2 (0.45) KDM4EALDH1A1HPGDMAPTTSHR
Ammonia Solution, Strong SCHEMBL30995385 0.78 KDM4E (0.45) KDM4EALDH1A1HPGDMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102531946-A 3-methoxybenzamide (MBA) derivant as well as preparation method and application thereof UNIV SHANDONG 2012-07-04 CN claimed
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 US disclosed
CN-104981469-B Antimicrobial 罗格斯新泽西州立大学 2018-03-20 CN disclosed
CN-107324975-A Direct hydroxylation or amination method of photocatalytic benzene and derivatives thereof 中国科学院理化技术研究所 2017-11-07 CN disclosed
CN-104981469-A Antimicrobial agents UNIV RUTGERS 2015-10-14 CN disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
CN-101404989-A Antibacterial agent PROLYSIS LTD (GB) 2009-04-08 CN disclosed
EP-1996180-A1 ANTIBACTERIAL AGENTS Prolysis Limited (GB) 2008-12-03 EP disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed
CN-1580055-A Quinolone carboxylic acid derivatives and their salts XINCHUANG MEDICINE SCIENCE TEC (CN) 2005-02-16 CN disclosed
CN-1028226-C 4-Oxoquinoline-3-carboxylic acid derivatives, their preparation and their use UBE INDUSTRIES (JP) 1995-04-19 CN disclosed
CN-1040977-A The preparation and the use of 4-Oxoquinoline-3-carboxylic acid derivative UBE INDUSTRIES (JP) 1990-04-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191420-A1 ANTIBACTERIAL AGENTS ALK, ARG1, ROS1 KDM4E 1251/4885ALDH1A1 740/4885HPGD 3902/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 KDM4E 2407/4885ALDH1A1 800/4885HPGD 3468/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 KDM4E 2407/4885ALDH1A1 800/4885HPGD 3468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.